Literature DB >> 28988204

Effect of bisphosphonates on knee replacement surgery.

Tuhina Neogi1, Shanshan Li1, Christine Peloquin1, Devyani Misra1, Yuqing Zhang1.   

Abstract

PURPOSE: Bone remodelling as a therapeutic target in knee osteoarthritis (OA) has gained much interest, but the effects of antiresorptive agents on knee OA have been conflicting, with no studies to date examining the effects of bisphosphonate use on the clinically relevant endpoint of knee replacement (KR) surgery.
METHODS: We used data from The Health Improvement Network (THIN), a general practitioner electronic medical records representative of the general UK population. We identified older women who had initiated bisphosphonate use after their incident knee OA diagnosis. Each bisphosphonate initiator was propensity score-matched with a non-initiator within each 1-year cohort accrual block. The effect of bisphosphonates on the risk of KR was assessed using Cox proportional hazard regression. Sensitivity analyses to address residual confounding were also conducted.
RESULTS: We identified 2006 bisphosphonate initiators, who were matched to 2006 non-initiators(mean age 76, mean body mass index 27), with mean follow-up time of 3 years. The crude incidence rate of KR was 22.0 per 1000 person-years among the initiators, and 29.1 among the non-initiators. Bisphosphonate initiators had 26% lower risk of KR than non-initiators(HR 0.74, 95% CI 0.59 to 0.93); these results were similar when additionally adjusted for potential confounders in the propensity score (HR 0.76, 95% CI 0.60 to 0.95). Results of sensitivity analyses supported this protective effect.
CONCLUSIONS: In this population-based cohort of older women with incident knee OA, those with incident bisphosphonate users had lower risk of KR than non-users of bisphosphonates, suggesting a potential beneficial effect of bisphosphonates on knee OA. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  knee osteoarthritis; orthopedic surgery; treatment

Mesh:

Substances:

Year:  2017        PMID: 28988204      PMCID: PMC6374039          DOI: 10.1136/annrheumdis-2017-211811

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Subjects with diffuse idiopathic skeletal hyperostosis have an increased burden of coronary artery disease: An evaluation in the COPDGene cohort.

Authors:  Sytse F Oudkerk; Firdaus A A Mohamed Hoesein; Willem PThM Mali; F Cumhur Öner; Jorrit-Jan Verlaan; Pim A de Jong; Gregory L Kinney; John Hokanson; David Lynch; Edwin K Silverman; Matthew J Budoff; Elizabeth A Regan
Journal:  Atherosclerosis       Date:  2019-05-30       Impact factor: 5.162

2.  Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions: A Randomized Clinical Trial.

Authors:  Guoqi Cai; Dawn Aitken; Laura L Laslett; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Catherine Hill; Lyn March; Anita E Wluka; Yuanyuan Wang; Benny Antony; Leigh Blizzard; Tania Winzenberg; Flavia Cicuttini; Graeme Jones
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

3.  Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.

Authors:  C Zeng; T Neogi; A T Chan; J Wei; D Misra; N Lu; H K Choi; G Lei; Y Zhang
Journal:  Osteoarthritis Cartilage       Date:  2022-01-11       Impact factor: 6.576

4.  Effects of medications on incidence and risk of knee and hip joint replacement in patients with osteoarthritis: a systematic review and meta-analysis.

Authors:  Beibei Cui; Yuehong Chen; Yunru Tian; Huan Liu; Yupeng Huang; Geng Yin; Qibing Xie
Journal:  Adv Rheumatol       Date:  2022-06-27

5.  Effect of alendronate sodium plus vitamin D3 tablets on knee joint structure and osteoarthritis pain: a multi-center, randomized, double-blind, placebo-controlled study protocol.

Authors:  Hui-Ming Peng; Xi-Sheng Weng; Ye Li; Bin Feng; Wenwei Qian; Dao-Zhang Cai; Chang Zhao; Zhen-Jun Yao; Yi Yang; Chi Zhang; Shengcheng Wan
Journal:  BMC Musculoskelet Disord       Date:  2022-06-17       Impact factor: 2.562

6.  Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis.

Authors:  Kai-di Wang; Xiang Ding; Nan Jiang; Chao Zeng; Jing Wu; Xian-Yi Cai; Aubryanna Hettinghouse; Asya Khleborodova; Zi-Ning Lei; Zhe-Sheng Chen; Guang-Hua Lei; Chuan-Ju Liu
Journal:  Ann Rheum Dis       Date:  2021-12-01       Impact factor: 27.973

7.  A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients - ZAP2.

Authors:  Dawn Aitken; Laura L Laslett; Guoqi Cai; Catherine Hill; Lyn March; Anita E Wluka; Yuanyuan Wang; Leigh Blizzard; Flavia Cicuttini; Graeme Jones
Journal:  BMC Musculoskelet Disord       Date:  2018-07-18       Impact factor: 2.362

8.  Efficacy of bisphosphonates in specific knee osteoarthritis subpopulations: protocol for an OA Trial Bank systematic review and individual patient data meta-analysis.

Authors:  Leticia A Deveza; Sita M A Bierma-Zeinstra; Willem Evert van Spil; Win Min Oo; Bruno T Saragiotto; Tuhina Neogi; Marienke van Middelkoop; David J Hunter
Journal:  BMJ Open       Date:  2018-12-19       Impact factor: 2.692

Review 9.  Bisphosphonates, Bone and Joint Pain.

Authors:  Michel Villatoro-Villar; C Kent Kwoh
Journal:  Curr Osteoporos Rep       Date:  2021-07-03       Impact factor: 5.096

10.  Defactinib attenuates osteoarthritis by inhibiting positive feedback loop between H-type vessels and MSCs in subchondral bone.

Authors:  Yanjun Hu; Hangtian Wu; Ting Xu; Yutian Wang; Hanjun Qin; Zilong Yao; Peisheng Chen; Yongheng Xie; Zhiguo Ji; Kaifan Yang; Yu Chai; Xianrong Zhang; Bin Yu; Zhuang Cui
Journal:  J Orthop Translat       Date:  2020-05-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.